SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-170177
Filing Date
2022-06-08
Accepted
2022-06-08 16:06:01
Documents
13
Period of Report
2022-06-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d311733d8k.htm   iXBRL 8-K 42099
2 EX-10.1 d311733dex101.htm EX-10.1 96894
  Complete submission text file 0001193125-22-170177.txt   288725

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA virx-20220608.xsd EX-101.SCH 2845
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE virx-20220608_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE virx-20220608_pre.xml EX-101.PRE 11254
7 EXTRACTED XBRL INSTANCE DOCUMENT d311733d8k_htm.xml XML 3346
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 221003544
SIC: 2834 Pharmaceutical Preparations